Seeking Alpha

Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study ...

- ASC30 oral once-daily tablet demonstrated a 6.5% placebo-adjusted mean body weight reduction from baseline after four-week treatment using weekly doses with titrations of 2 mg, 10 mg, 20 mg, and 40 ...
ascopubs.org

Phase Ib study of the combination of regorafenib with conventional chemotherapy in patients with newly diagnosed multi-metastatic Ewing sarcoma: The Rego-Inter-Ewing-1 study.

ONITT: A phase I study of nanoliposomal irinotecan with talazoparib or temozolomide in children and young adults with recurrent or refractory solid tumors. Promoting Resilience in Stress Management ...
ascopubs.org

A phase I/Ib study of olaparib and ASTX727 in BRCA 1/2- and HRD-mutated tumors.

A phase 1/2 study of JK06, a 5T4 antibody drug conjugate, in patients with unresectable locally advanced or metastatic cancer. RYZ101 (225Ac-DOTATATE) in patients with estrogen receptor-positive, ...
Morningstar

Bambusa Therapeutics Announces First Patient Dosed in Phase Ib Proof-of-Concept COPD Study of BBT002, Reinforcing Bispecific Pipeline Momentum

BOSTON, Jan. 6, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies for immunology & inflammation (I&I), today ...